主要會議 第1天 - 2025年10月21日 2025年10月21日（星期二） - 日本時間（GMT+09:00）

Chugai has established various proprietary antibody engineering technologies. To effectively maximize the value of these established technologies, we have been applying them sequentially to multiple targets across disease areas. Several examples will be shared in this presentation.

FcRn functions as a recycling receptor to maintain levels of IgG and albumin. Efgartigimod (Vyvgart™) is a FcRn antagonist approved for treatment of IgG driven diseases. In this talk the engineering of a next-generation FcRn blocker with prolonged duration of effect will be discussed. Moreover, we describe the development of an anti-IgA monoclonal antibody that can actively remove IgA from the circulation. Given the abundancy of IgA in human serum (1-3 mg/mL), both Fab and Fc engineering were needed.

This talk will explore cutting-edge strategies for antibody display selections, highlighting their impact on the discovery of novel potential therapeutics, for established and novel format of antibodies: from Fab to VHH. The presentation will cover advancements in display technology approaches to optimize the selection of antibodies with precise features, presenting case studies demonstrating successful applications (e.g., anti-ID, pH sensitivity, specific epitope recognition). Future directions and unmet needs in the field to accelerate precision medicine and the development of new therapies will also be covered.

This presentation will explore how Adimab has revolutionized antibody discovery, growing from an innovative startup into a leading platform technology company. We will examine key technological breakthroughs in our platform, focusing on synthetic antibody library evolution, advances in multispecific generation, and novel approaches to developability optimization. Join us to learn how Adimab's engineering-driven approach is shaping the future of therapeutics.

Quick feedback on what people designed and produced and how these act in the system is essential for the development of novel molecules and formats, but this is challenging. Rigaku developed a 'Molecular projector, MoleQlyze' that can image large molecules and complexes in a solution without prerequisite information and crystallization/freezing/fixation/labeling processes. This enables overnight direct epitope mapping, molecular defects and aging monitoring during culture and purification processes, nucleotide-protein quantitation of vector complexes, and observation of defects in particles with the molecular 3D image under given conditions.

For more information about presenting in this session, please contact Michael Keenan at Michael.Keenan@informa.com

A recent clinical trial involving MOv18 IgE, provided tantalising evidence of IgE’s potential for the treatment of cancer. Epsilogen is conducting a phase Ib trial in which translational data will be collated to further understand mechanisms associated with IgE therapy. In addition, Epsilogen has established a pipeline of anti-tumoral IgEs and two novel platforms: bispecific IgE and a hybrid antibody which combines the effector functions of IgE and IgG.

At OmniAb, we build, shape and mine custom, naturally optimized human immune repertoires in divergent species to discover next generation biotherapeutics. Using our high throughput single B cell screening xPloration platform combined with an AI-guided NGS workflow, we identify drug-like leads, bypassing extensive ex-vivo engineering. We show examples of campaigns across various animal platforms that yielded broad and complementary epitope coverage of disparate specific targets, with a range of affinities, and favorable developability characteristics, increasing options for our partners.

Effective and specific non-opioid therapeutics for chronic pain with high efficacy and no side effects are urgently needed. We have reported that mouse scFv95, a small molecule specifically recognizing and blocking P2X4R, is a promising candidate for further characterization and humanization. Nine humanized scFv (hscFv) variants against an extracellullar fragment of human P2X4 were generated via CDR grafting using E. coli production and His-Tag protein purification. Affinity measurement by ELISA and SDS indicates binding affinity in the nanomolar range. More than 2/3 of humanized small molecules showed higher affinity than the parental protein. Octet measurements further revealed the lead HC3-LC3 had binding kinetics of KD = 2.5 × 10-9 M. No endotoxin or in vivo toxicity is noted. Functional validation in vivo in a trigeminal nerve injury model finds reversal of pain related behaviors within two weeks after a single dose (4 mg/kg, intranasal). The details of the development and characterization of a lead P2X4 hscFv HC3-LC3 small molecule provided here constitute an original method whereby durable reversal of nerve injury hypersensitivity can be accomplished. This study opens new avenues for research to develop humanized non-opioid therapeutic interventions for chronic pain.

MabPair is a novel technology for making the next generation antibody combination products that are capable of targeting multiple molecules and pathways. The core technology is based on an antibody engineering platform that enables the production of two full length IgG molecules from a single production cell line. The technology platform can be used to develop therapeutic antibody products that contain a mixture of two different antibodies in a predefine ratio through the conventional antibody manufacture process. MabPair products can offer compelling advantages over bispecific antibodies or conventional antibody combination including abilities to achieve different level of target coverage for the two antibodies, full flexibility in choice of different Fc backbones for antibody effector function and pharmacokinetics profiles, streamlined regulatory and clinical development paths, and single-entity pricing power. Recently our first MabPair product was approved in China by NMPA. The talk will describe the process of generating MabPair products with case studies that highlight the unique feature of the platform and its potential applications in different therapeutic settings.

TfR1 is involved in iron uptake and cell growth. Many cancers express TfR1, but TfR1-targeted agents have safety risks. KK2260 is a REGULGENT™ technology-based bispecific antibody targeting TfR1 and EGFR. KK2260 resulted in EGFR-binding dependent TfR1 downregulation and demonstrated potent anticancer effect against EGFR-expressing tumors. Clinical study is ongoing (NCT06248411).

For more information about presenting in this session, please contact Michael Keenan at Michael.Keenan@informa.com